Currently, there are 131.16M common shares owned by the public and among those 51.71M shares have been available to trade.
The company’s stock has a 5-day price change of 4.19% and -8.24% over the past three months. PRME shares are trading -44.69% year to date (YTD), with the 12-month market performance down to -79.56% lower. It has a 12-month low price of $1.11 and touched a high of $7.07 over the same period. PRME has an average intraday trading volume of 1.92 million shares. The stock is trading above its simple moving averages at the SMA20, SMA50, and SMA200, as the current price level is off by 17.39%, 14.54%, and -40.09% respectively.
Institutional ownership of Prime Medicine Inc (NASDAQ: PRME) shares accounts for 28.66% of the company’s 131.16M shares outstanding.
It has a market capitalization of $212.04M and a beta (3y monthly) value of 1.59. The earnings-per-share (ttm) stands at -$1.66. Price movements for the stock have been influenced by the stock’s volatility, which stands at 5.05% over the week and 7.23% over the month.
Earnings per share for the fiscal year are expected to increase by 23.33%, and 20.83% over the next financial year. EPS should grow at an annualized rate of 18.30% over the next five years, compared to -124.13% over the past 5-year period.
Looking at the support for the PRME, a number of firms have released research notes about the stock. Citigroup stated their Neutral rating for the stock in a research note on May 27, 2025, with the firm’s price target at $1.50. H.C. Wainwright was of a view on May 20, 2025 that the stock is Neutral, while JMP Securities gave the stock Mkt Outperform rating on December 10, 2024, issuing a price target of $10. H.C. Wainwright on their part issued Buy rating on May 20, 2024.
